Experience at Son Espases University Hospital with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd) as first line treatment in multiple myeloma

被引：0
|
作者：
Monsonis, Lola Piquer [1 ]
Sampalo, Maria Gali [1 ]
Montana, Albert Perez [1 ]
Raga, Jose Maria Sanchez [1 ]
Mayol, Antonia Sampol [1 ]
机构：
[1] Hosp Univ Son Espases, Palma De Mallorca, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P158
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [41] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
    Fazio, Francesca
    Franceschini, Luca
    Tomarchio, Valeria
    Rago, Angela
    Garzia, Maria Grazia
    Cupelli, Luca
    Bongarzoni, Velia
    Andriani, Alessandro
    Gumenyuk, Svitlana
    Tafuri, Agostino
    Siniscalchi, Agostina
    Piciocchi, Alfonso
    De Fabritiis, Paolo
    De Rosa, Luca
    di Toritto, Tommaso Caravita
    Annibali, Ombretta
    Cantonetti, Maria
    Petrucci, Maria Teresa
    EJHAEM, 2022, 3 (01): : 121 - 128
  • [43] REAL EXPERIENCE OF TREATMENT WITH DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE FIRST LINE AND IN RECALL/REFRACTORY
    Fernandez, Moreno F.
    Sole, Rodriguez M.
    Dominguez, Rodriguez J. F.
    HAEMATOLOGICA, 2020, 105 : 367 - 367
  • [44] Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis
    Costa, Bruno Almeida
    Costa, Thomaz Alexandre
    Pak, Kevin
    Patel, Aesha
    Felix, Nicole
    Mouhieddine, Tarek H.
    Richter, Joshua
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1411 - 1414
  • [45] DARATUMUMAB COMBINED WITH DEXAMETHASONE AND LENALIDOMIDE OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: REPORT FROM THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP
    Fazio, F.
    Franceschini, L.
    Tomarchio, V.
    Rago, A.
    Garzia, M. G.
    Cupelli, L.
    Bongarzoni, V.
    Rosati, S.
    Gumenyku, S.
    Antolino, G.
    Siniscalchi, A.
    Proietti, G.
    Piciocchi, A.
    De Fabritiis, P.
    De Rosa, L.
    Caravita, T.
    Annibali, O.
    Cantonetti, M.
    Petrucci, M. T.
    HAEMATOLOGICA, 2021, 106 (10) : 92 - 92
  • [46] Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
    Dimopoulos, Meletios
    Weisel, Katja
    Moreau, Philippe
    Anderson, Larry D., Jr.
    White, Darrell
    San-Miguel, Jesus
    Sonneveld, Pieter
    Engelhardt, Monika
    Jenner, Matthew
    Corso, Alessandro
    Duerig, Jan
    Pavic, Michel
    Salomo, Morten
    Casal, Eva
    Srinivasan, Shankar
    Yu, Xin
    Nguyen, Tuong Vi
    Biyukov, Tsvetan
    Peluso, Teresa
    Richardson, Paul
    LEUKEMIA, 2021, 35 (06) : 1722 - 1731
  • [47] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Pelligra, C.
    Guo, S.
    Parikh, K.
    Zhang, S.
    Krotneva, M.
    Onyekwere, U.
    Clancy, Z.
    VALUE IN HEALTH, 2018, 21 : S254 - S254
  • [48] Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
    Meletios Dimopoulos
    Katja Weisel
    Philippe Moreau
    Larry D. Anderson
    Darrell White
    Jesus San-Miguel
    Pieter Sonneveld
    Monika Engelhardt
    Matthew Jenner
    Alessandro Corso
    Jan Dürig
    Michel Pavic
    Morten Salomo
    Eva Casal
    Shankar Srinivasan
    Xin Yu
    Tuong Vi Nguyen
    Tsvetan Biyukov
    Teresa Peluso
    Paul Richardson
    Leukemia, 2021, 35 : 1722 - 1731
  • [49] CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN MULTIPLE MYELOMA DIAGNOSTIC PATIENTS
    De Miguel Llorente, D.
    Gil Perez, A.
    Diaz Morfa, M.
    Golbano Lopez, N.
    Vazquez Ramo, A.
    Guillen Lopez, H.
    Nuevo Lopez, I
    Perez Ortega, A.
    Arbeteta Juanis, J.
    Subira Perez, D.
    Morales Sanz, D.
    Garcia Ramirez, P.
    Santos Montero, A. B.
    Herrero Martin, S.
    HAEMATOLOGICA, 2019, 104 : 194 - 195
  • [50] CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA
    De Miguel, Llorente Dunia
    Gil, Perez Angela
    Merchan, Munoz Beatriz
    Nuevo, Lopez Irene
    Perez, Ortega Alba
    Guillen, Garcia Helga
    Vazquez, Ramo Alejandro
    Subira, Perez Dolores
    Golbano, Lopez Nuria
    Santos, Montero Ana Belen
    Morales, Sanz Dolores
    Arbeteta, Juanis Jaime
    HAEMATOLOGICA, 2020, 105 : 150 - 151
12345